The role of SKP2 in docetaxel response and resistance in prostate cancer.

@article{Khushman2011TheRO,
  title={The role of SKP2 in docetaxel response and resistance in prostate cancer.},
  author={Moh'd Khushman and Ok Hee Hwang and Evelyn R. Barrack and P. Gangi Reddy and Clara Hwang},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={e15058}
}
e15058 Background: Docetaxel, a microtubule-targeting agent, is the current standard of care for symptomatic metastatic castrate-resistant prostate cancer. Understanding the mechanisms underlying docetaxel resistance may help clinicians tailor patient treatment and develop strategies to overcome resistance. Our analysis identified the underexpression of S… CONTINUE READING